The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression

Autor: Tim Maughan, Davide Trapani, Daniela Furlan, Ian Tomlinson, Hayley Davis, Rachael Thomas, Simon J. Leedham, Annabelle Lewis, Lily Goodyer-Sait, Connor Woolley, Marketa Tomkova, Ceres Fernandez-Rozadilla, Skirmantas Kriaucionis, Laura Chegwidden, Nora Sahnane, Claire Palles
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Databases
Factual

lcsh:Medicine
0302 clinical medicine
Gene expression
Cancer genomics
Cancer epigenetics
lcsh:Science
Promoter Regions
Genetic

Cancer genetics
0303 health sciences
Multidisciplinary
Functional genomics
Methylation
Chromatin
3. Good health
DNA-Binding Proteins
Gene Expression Regulation
Neoplastic

030220 oncology & carcinogenesis
DNA methylation
Microsatellite Instability
Colorectal Neoplasms
MutL Protein Homolog 1
functional genomics
congenital
hereditary
and neonatal diseases and abnormalities

cancer genetics
Biology
MLH1
Polymorphism
Single Nucleotide

Article
03 medical and health sciences
medicine
Humans
Genetic Predisposition to Disease
RNA
Messenger

Allele
Gene
neoplasms
Alleles
030304 developmental biology
cancer genomics
lcsh:R
Microsatellite instability
nutritional and metabolic diseases
DNA Methylation
medicine.disease
digestive system diseases
cancer epigenetics
Case-Control Studies
Cancer research
chromatin
lcsh:Q
CpG Islands
Transcription Factors
Zdroj: Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-10 (2019)
Thomas, R, Trapani, D, Goodyer-sait, L, Tomkova, M, Fernandez-rozadilla, C, Sahnane, N, Woolley, C, Davis, H, Chegwidden, L, Kriaucionis, S, Maughan, T, Leedham, S, Palles, C, Furlan, D, Tomlinson, I & Lewis, A 2019, ' The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression ', Scientific Reports, vol. 9, no. 1 . https://doi.org/10.1038/s41598-019-49952-x
DOI: 10.1038/s41598-019-49952-x
Popis: The raw data is available on Mendeley at https://data.mendeley.com/datasets/hfpbctm7tg/draft?a=1c91e494-cadc-4be0-a8ff-91d8736a28e7 © The Author(s) 2019. Expression of the mismatch repair gene MutL homolog 1 (MLH1) is silenced in a clinically important subgroup of sporadic colorectal cancers. These cancers exhibit hypermutability with microsatellite instability (MSI) and differ from microsatellite-stable (MSS) colorectal cancers in both prognosis and response to therapies. Loss of MLH1 is usually due to epigenetic silencing with associated promoter methylation; coding somatic mutations rarely occur. Here we use the presence of a colorectal cancer (CRC) risk variant (rs1800734) within the MLH1 promoter to investigate the poorly understood mechanisms of MLH1 promoter methylation and loss of expression. We confirm the association of rs1800734 with MSI+ but not MSS cancer risk in our own data and by meta-analysis. Using sensitive allele-specific detection methods, we demonstrate that MLH1 is the target gene for rs1800734 mediated cancer risk. In normal colon tissue, small allele-specific differences exist only in MLH1 promoter methylation, but not gene expression. In contrast, allele-specific differences in both MLH1 methylation and expression are present in MSI+ cancers. We show that MLH1 transcriptional repression is dependent on DNA methylation and can be reversed by a methylation inhibitor. The rs1800734 allele influences the rate of methylation loss and amount of re-expression. The transcription factor TFAP4 binds to the rs1800734 region but with much weaker binding to the risk than the protective allele. TFAP4 binding is absent on both alleles when promoter methylation is present. Thus we propose that TFAP4 binding shields the protective rs1800734 allele of the MLH1 promoter from BRAF induced DNA methylation more effectively than the risk allele. Funding was provided by a Medical Research Council New Investigator Research Grant (MR/P000738/1). Core funding to the Wellcome Trust Centre for Human Genetics was provided by the Wellcome Trust (090532/Z/09/Z). D.T., N.S. and D.F. were supported by the EPIGENOMICS FLAGSHIP PROJECT- EPIGEN (project number 08934412) and by University of Insubria. M.T. and S.K. were funded by Ludwig Cancer Research.
Databáze: OpenAIRE